KRAS and non-small cell lung carcinoma: The Food and Drug Administration (FDA) pooled data from 12 registrational clinical trials investigating ICI with or without chemotherapy, showing that patients with KRAS-mutated NSCLC derived the most significant benefit from the combination of chemotherapy-ICI as compared to ICI or chemotherapy alone11.